SEC Comment Letter for NYMOX PHARMACEUTICAL CORP (NYMXF) (CIK 0001018735) (NYMXF) — Apr 10, 2020
NYMOX PHARMACEUTICAL CORP (NYMXF) (CIK 0001018735)
Date: April 10, 2020 · CIK: 0001018735 · Accession: 0000000000-20-003129
AI Filing Summary & Sentiment
File numbers found in text: 333-237564
Letter
April 10, 2020 Paul Averback, M.D. Chief Executive Officer and President Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, The Bahamas Re:Nymox Pharmaceutical Corporation Registration Statement on Form F-3 Filed April 3, 2020 File No. 333-237564 Dear Dr. Averback: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: M. Richard Cutler, Esq.
Show Raw Text
April 10, 2020
Paul Averback, M.D.
Chief Executive Officer and President
Nymox Pharmaceutical Corporation
Bay & Deveaux Streets
Nassau, The Bahamas
Re:Nymox Pharmaceutical Corporation
Registration Statement on Form F-3
Filed April 3, 2020
File No. 333-237564
Dear Dr. Averback:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: M. Richard Cutler, Esq.